Search Tag: Q1 report

IT Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more

ICU Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more

IMAGING Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more

Executive Health Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more

Cardiology Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more

Finance Management

2024 29 Apr

  First-quarter highlights   Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million) Income from operations EUR -824 million, including...Read more